A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Phase 1 Completed 44 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

A dose escalation study to determine the safety and maximum tolerated dose (MTD) of IMC-3C5 in subjects with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available.

Timeline

Start: 2011-03
Primary completion: 2014-07
Completion: 2014-07

Publications

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24. doi: 10.1007/s00280-016-3134-3. Epub 2016 Aug 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMC-3C5	Monoclonal antibody	5 mg/kg	Intravenous
Subject	IMC-3C5	Monoclonal antibody	10 mg/kg	Intravenous
Subject	IMC-3C5	Monoclonal antibody	20 mg/kg	Intravenous
Subject	IMC-3C5	Monoclonal antibody	30 mg/kg	Intravenous

A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications